INVANZ Drug Patent Profile
✉ Email this page to a colleague
When do Invanz patents expire, and when can generic versions of Invanz launch?
Invanz is a drug marketed by Msd Sub Merck and is included in one NDA.
The generic ingredient in INVANZ is ertapenem sodium. There are eight drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ertapenem sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Invanz
A generic version of INVANZ was approved as ertapenem sodium by ACS DOBFAR SPA on April 16th, 2018.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for INVANZ?
- What are the global sales for INVANZ?
- What is Average Wholesale Price for INVANZ?
Summary for INVANZ
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 58 |
Clinical Trials: | 21 |
Patent Applications: | 5,158 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for INVANZ |
What excipients (inactive ingredients) are in INVANZ? | INVANZ excipients list |
DailyMed Link: | INVANZ at DailyMed |
![INVANZ drug patent expirations Drug patent expirations by year for INVANZ](/p/graph/s/t/INVANZ-patent-expirations.png)
![Drug Prices for INVANZ](/p/graph/drug-price/INVANZ.png)
Recent Clinical Trials for INVANZ
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Todd C. Lee MD MPH FIDSA | Phase 2 |
Iterum Therapeutics, International Limited | Phase 3 |
Iterum Therapeutics, US Limited | Phase 3 |
Pharmacology for INVANZ
Drug Class | Penem Antibacterial |
Paragraph IV (Patent) Challenges for INVANZ
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
INVANZ | Injection | ertapenem sodium | 1 g/vial | 021337 | 1 | 2012-12-21 |
US Patents and Regulatory Information for INVANZ
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for INVANZ
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | ⤷ Sign Up | ⤷ Sign Up |
Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | ⤷ Sign Up | ⤷ Sign Up |
Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | ⤷ Sign Up | ⤷ Sign Up |
Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for INVANZ
See the table below for patents covering INVANZ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Russian Federation | 2117659 | ПРОИЗВОДНЫЕ КАРБАПЕНЕМА, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И ГИДРОЛИЗУЕМЫЕ IN VIVO ЭФИРО (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТИБАКТЕРИАЛЬНОЙ АКТИВНОСТЬЮ, ПРОИЗВОДНЫЕ ПИРРОЛИДИН-4-ИЛТИОЛА И ЗАЩИЩЕННЫЕ ПРОИЗВОДНЫЕ ПИРРОЛИДИНА-4-ИЛТИОЛА (CARBOPENEM DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND HYDROLYZED IN VIVO ESTERS (VARIANTS), METHOD OF SYNTHESIS (VARIANTS), PHARMACEUTICAL COMPOSITION SHOWING ANTIBACTERIAL ACTIVITY, DERIVATIVES OF PYRROLIDINE-4-YLTHIOL AND PROTECTED DERIVATIVES OF PYRROLIDINE-4-YLTHIOL) | ⤷ Sign Up |
African Regional IP Organization (ARIPO) | 9300480 | ⤷ Sign Up | |
United Kingdom | 9612668 | ⤷ Sign Up | |
Ukraine | 62920 | CARBAPENEME ANTIBIOTIC, A COMPOSITION AND A METHOD FOR THE PREPARATION | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for INVANZ
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0579826 | CA 2002 00025 | Denmark | ⤷ Sign Up | PRODUCT NAME: ERTAPENEM OG FARMACEUTISK ACCEPTABLE SALTE DERAF |
0579826 | 10299041 | Germany | ⤷ Sign Up | PRODUCT NAME: ERTAPENEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE HIERVON, EINSCHLIESSLICH ERTAPENEM-NATRIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418 |
0863901 | PA2004008 | Lithuania | ⤷ Sign Up | PRODUCT NAME: ERTAPENEMUM ([4R,5S,6S]-3-[(3S,5S)-5-[(3-KARBOKSIFENIL) AMINO]KARBONIL]-3-PIROLIDINIL]TIO]-6-[(1R)-1HIDROKSIETIL]-4-METIL-7-OKSO-1-AZABICIKLO-[3.2.0]HEPT-2-EN-2-KARBOKSIRUGSTIS; REGISTRATION NO/DATE: 03/8043/3 20030328 |
0579826 | C300104 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ERTAPENEM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ERTAPENEMNATRIUM; NAT. REGISTRATION NO/DATE: EU/1/02/216/001 20020418; FIRST REGISTRATION: EU/1/02/216/001 20020418 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |